medisourceasia.com

Industry News


About 
medisourceasia

Magazine
Industry News
Global Trends
Events Calendar
Web Links

Web Gallery

Advertising  Info

Contact

 

Medical Equipment Cos Ask Govt To Bring Down Import Duty To 5% In Union Budget

Medical equipment manufacturers and providers have jointly sought a reduction in import duty on medical equipments in the Union Budget 2008-09 for the benefit of industry and patients.

The Indian healthcare industry is on the threshold of a major growth trajectory driven by an upsurge in lifestyle diseases. This has resulted in a higher incidence of indispensable surgical interventions in India carried out with imported equipments. Present import duty on equipment varies from 12 percent to 120 percent in products ranging from kits to large equipment.

From the standpoint of a medical equipment manufacturer, GE Healthcare calls to rationalize import duties across all medical equipments at a standard rate of 5 percent bringing it in line with other Asian countries and doing away with multiple rates for different equipments.

According to the Pricewater-house Coopers in its report, 'Healthcare in India : Emerging market report 2007', the Indian healthcare sector is valued at US $34 billion and is projected to grow to nearly $40 billion by 2012. In the backdrop of a promising future, government should grant infrastructure industry status to healthcare as it is a key driver for the growth and development of the country. India has the potential to cement its place as one of the world's major healthcare hubs, pointed out the V Raja, president and CEO, GE Healthcare South Asia.

It is also important for the government to encourage indigenous manufacture of medical equipment with a view to reduce the end cost of the product and thereby benefit the patient in the form of lower cost of treatment, by allowing import of raw materials, components and spares for manufacturing of medical equipments at zero percent import duty. Import of parts for servicing medical equipments is subjected to import duty at 21 percent and refund is made to the extent of 12 percent if proof of usage of the same is provided. As spare parts of medical equipments can only be used for servicing medical equipment, the need for furnishing proof of usage or the scope for any misuse of the same just does not arise and therefore there is no need to levy a higher duty initially and then subject it to refund at a subsequent stage, simplifying the procedure for both the assesses and administration saving costs for both the parties.

All medical equipments are subjected to service contract which attracts service tax at the rate of 12.5 percent. The impact of this is again passed on to the patients. Either, the service tax should to be completely removed on medical equipments, service contracts or reduced to 4% lowering the burden on the patients, stated the president and CEO, GE Healthcare South Asia.

Going by the potential for growth in terms of advanced infrastructure and ability of Indian surgeons and physicians to perform high tech interventions, the government should look at slashing import duty not just on device and equipment but also the consumables like Mannequins and artificial blood vessels products used to train the doctors and para medical staff in emergency medicine, critical care and surgeries, said Dr. NK Venkataramana, vice chairman and neurosurgeon  BGS Global Hospitals and director, Global Neuro Sciences.

Most of the consumables and devices are not manufactured in India and these are life saving equipment used by medical professionals to be adept in surgery and emergency medicine. Present import duty for these is at 120 percent and just not affordable even by corporate hospitals to increase their volumes in such products, explained Dr. Venkataramana.

On the diagnostic kits front, detection of HIV Antibodies is exempt from Customs and Excise duties under List 4 and CVD/CED under the Central Excise Act. Companies are seeking exemption in customs and excise duty for imported and local manufacturers of kits of Hepatitis C, malaria, tuberculosis as it falls with the category of life saving drugs. Abolishing the duty will give price advantage for export and the price relief for the Indian patients stated Dr. Shama Bhat, Bhat Biotech.

(Ref: Hospital Equipment & Solutions | March 2008)


Next
 

Other News

Fresenius Net Income Surges By 24% In 2007 At Euro 11,358 Million
India No More Hot Offshore R&D Centre
Bigtec Invests Rs. 10 Cr For Advanced Biotech Lab At IISc Campus
Marck To Enter Malaysia, S’pore & Indonesia Markets
RG Stone Urology Plans Telemedicine, Satellite Centres In India
Cardiac Completes Certification For HeartCentrix With NextGen

Archives

Advertisement

 

 


Back | Back To Top | Previous | Next